Call us at 888-525-1262 to schedule a FREE initial consultation.
Drug Description: Tequin is an antibiotic that is commonly used to treat adults with lung, sinus and urinary tract infections as well as certain sexually transmitted diseases. Tequin in an antibiotic in the class of drugs called fluoroquinolones, which also contains Ciro, Levaquin and Avelox. This recent study indicates that the risk of disabetes is specific to Tequin and is not a problem with the entire class of drugs. However, the entire class of drugs has been linked to tendon ruptures. Last year Tequin had worldwide sales of $150 million, including $100 million in the United States
Tequin to be Pulled from the Market
On May 1, 2006, Bristol-Myers Squibb stated that it will cease making and selling its antibiotic Tequin. Teguin has been linked to serious cases of diabetes and other potentially fatal blood sugar abnormalities. According to a Canadian study that was supposed to appear in the New England Journal of Medicine in March 30, 2006 but were released early due to the life threatening nature of the side effects, Teguin users had 17 times greater risk of developing serious diabetes and 4 times greater risk of being hospitalized with low blood sugar complications than patients using other antibiotics. Tequin (generic: gatifloxacin) received FDA approval in 1999. Consumer group Public Citizen stated that there have been 388 patients with blood-sugar irregularities linked with Tequin since January 1, 2000. Those cases included 20 deaths and 159 hospitalizations. The consumer group and various physicians called for the drug’s withdrawal, claiming it carries great health risks but few benefits over similar drugs.
Dr. David Juurlink of the Sunnybrook and Women’s College Health Sciences Center in Toronto, questioned whether the drug should be immediately removed from the market. Other prominent physicians believed that a black box warning should be added to Tequin’s warning label.
Warning for Diabetics May Apply to Anyone Taking Tequin
In early 2006, Bristol Myers Squibb and the FDA added a warning to the drug’s label notifying diabetics not to take Tequin. However, the study’s author said the blood-sugar problem can happen to anybody whether they have diabetes or not, and it usually occurs within a few days of taking the drug. The risk of the drug might be even greater than the study revealed because it was only based on hospital data. If a patient suffered these side effects but wasn’t hospitalized, or died, they would not have been included in the study data.
If you or a loved one has suffered injury as a result of taking Tequin we can help. Please click here to contact Pearson Law or call our toll free number at 888-525-1262 to schedule a FREE initial consultation.